AHCPR Issues Colorectal Cancer Screening Evidence Report

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 3
Volume 6
Issue 3

ROCKVILLE, Md--In the first report issued under its new Evidence-based Practice Initiative, the Agency for Health Care Policy and Research (AHCPR) has reaffirmed that early detection and treatment provide the primary means of preventing death from colorectal cancer.

ROCKVILLE, Md--In the first report issued under its new Evidence-basedPractice Initiative, the Agency for Health Care Policy and Research (AHCPR)has reaffirmed that early detection and treatment provide the primary meansof preventing death from colorectal cancer.

Among the conclusions of the report, based on a review of 3,500 citationsfrom the scientific literature (1966 to 1994):

  • Use of fecal occult blood testing followed by diagnostic evaluationand treatment for positive tests can cut colorectal cancer mortality by15% to 33%.
  • A 60-cm flexible sigmoidoscopy identifies nearly all cancers and polypsgreater than 1 cm in diameter and 75% to 80% of small polyps.
  • Sigmoidoscopy screening can reduce colorectal cancer mortality riskby 59% to 80%.
  • Indirect evidence supports the use of double-contrast barium enemain screening for colorectal cancer.
  • While screening colonoscopy offers the potential to both identify andremove cancers and premalignant lesions, no studies completed to date showan associated mortality reduction.
  • Detecting and removing polyps reduces the incidence of colorectal cancer,and removing early cancers lowers mortality. Although both double-contrastbarium enema and colonoscopy detect polyps and tumors, they have not beenstudied as screening tests.

  • © 1997 by PRR, Inc. All rights reserved.
Recent Videos
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.
According to Benjamin J. Golas, MD, PIPAC could be used as a bridging therapy before surgical debulking or between subsequent large surgical operations.
According to Benjamin Golas, MD, PIPAC is emerging as minimally invasive laparoscopic approach for patients with peritoneal carcinomatosis.
According to Ronan J. Kelly, deciding whether to give nivolumab- or durvalumab-based regimens in gastric cancers may rely on a patient’s frailty.
Five-year follow-up revealed that patients treated with nivolumab vs placebo in the phase 3 CheckMate 577 trial experienced a “doubling” of survival.
Patients treated with nivolumab in the phase 3 CheckMate 577 trial were less likely to experience progression-related treatment discontinuation vs placebo.
Testing a patient’s genetics may influence decisions such as using longer courses of radiotherapy, says Rachit Kumar, MD.
Related Content